Strides Pharma Science Limited will monetise its stake in subsidiary Pivot Path Private Limited in a transaction led by Ascent Capital, alongside co-investor Vintage Classic, valuing the entity at near ₹230 crore post-money. The company will realise near ₹100 crore while retaining near 20% ownership and also receive a primary capital infusion of ₹50 crore into the business.Read More
Strides Pharma to monetise stake in Pivot Path; company valued at ₹230 crore post-money
- by stefan